MCRB Annual FCF
-$125.33 M
+$113.31 M+47.48%
31 December 2023
Summary:
As of January 23, 2025, MCRB annual free cash flow is -$125.33 million, with the most recent change of +$113.31 million (+47.48%) on December 31, 2023. During the last 3 years, it has fallen by -$31.13 million (-33.04%). MCRB annual FCF is now -658.78% below its all-time high of $22.43 million, reached on December 31, 2016.MCRB Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MCRB Quarterly FCF
-$34.81 M
+$5.10 M+12.78%
30 September 2024
Summary:
As of January 23, 2025, MCRB quarterly free cash flow is -$34.81 million, with the most recent change of +$5.10 million (+12.78%) on September 30, 2024. Over the past year, it has increased by +$13.57 million (+28.04%). MCRB quarterly FCF is now -128.15% below its all-time high of $123.65 million, reached on September 30, 2021.MCRB Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MCRB TTM FCF
-$158.39 M
+$26.24 M+14.21%
30 September 2024
Summary:
As of January 23, 2025, MCRB TTM free cash flow is -$158.39 million, with the most recent change of +$26.24 million (+14.21%) on September 30, 2024. Over the past year, it has dropped by -$33.06 million (-26.38%). MCRB TTM FCF is now -358.12% below its all-time high of $61.36 million, reached on March 31, 2016.MCRB TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MCRB Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +47.5% | +28.0% | -26.4% |
| 3 y3 years | -33.0% | +38.2% | +33.6% |
| 5 y5 years | -93.4% | +38.2% | +33.6% |
MCRB Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -4254.7% | +47.5% | -153.8% | +56.8% | -5403.6% | +36.6% |
| 5 y | 5-year | -4254.7% | +47.5% | -128.2% | +56.8% | -588.7% | +36.6% |
| alltime | all time | -658.8% | +47.5% | -128.2% | +56.8% | -358.1% | +36.6% |
Seres Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$34.81 M(-12.8%) | -$158.39 M(-14.2%) |
| June 2024 | - | -$39.91 M(+13.1%) | -$184.64 M(+130.9%) |
| Mar 2024 | - | -$35.30 M(-27.0%) | -$79.97 M(-36.2%) |
| Dec 2023 | -$125.33 M(-47.5%) | -$48.38 M(-20.8%) | -$125.33 M(-6.0%) |
| Sept 2023 | - | -$61.05 M(-194.3%) | -$133.31 M(+0.2%) |
| June 2023 | - | $64.75 M(-180.3%) | -$133.08 M(-46.7%) |
| Mar 2023 | - | -$80.65 M(+43.1%) | -$249.89 M(+4.7%) |
| Dec 2022 | -$238.64 M(+8191.8%) | -$56.35 M(-7.4%) | -$238.64 M(+1.2%) |
| Sept 2022 | - | -$60.83 M(+16.8%) | -$235.72 M(+360.0%) |
| June 2022 | - | -$52.06 M(-25.0%) | -$51.25 M(+23.7%) |
| Mar 2022 | - | -$69.39 M(+29.9%) | -$41.44 M(+1339.7%) |
| Dec 2021 | -$2.88 M(-96.9%) | -$53.44 M(-143.2%) | -$2.88 M(-108.9%) |
| Sept 2021 | - | $123.65 M(-392.7%) | $32.41 M(-127.7%) |
| June 2021 | - | -$42.25 M(+37.0%) | -$117.17 M(+16.3%) |
| Mar 2021 | - | -$30.84 M(+69.9%) | -$100.72 M(+6.9%) |
| Dec 2020 | -$94.20 M(+21.5%) | -$18.15 M(-30.0%) | -$94.20 M(+4.3%) |
| Sept 2020 | - | -$25.93 M(+0.5%) | -$90.33 M(+9.1%) |
| June 2020 | - | -$25.79 M(+6.1%) | -$82.81 M(+19.8%) |
| Mar 2020 | - | -$24.32 M(+70.4%) | -$69.14 M(-10.8%) |
| Dec 2019 | -$77.52 M | -$14.28 M(-22.5%) | -$77.52 M(+53.9%) |
| Sept 2019 | - | -$18.42 M(+51.8%) | -$50.38 M(-9.3%) |
| June 2019 | - | -$12.13 M(-62.9%) | -$55.53 M(-20.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$32.70 M(-354.2%) | -$69.77 M(+7.7%) |
| Dec 2018 | -$64.79 M(-19.2%) | $12.86 M(-154.6%) | -$64.79 M(-34.5%) |
| Sept 2018 | - | -$23.56 M(-10.7%) | -$98.95 M(+24.5%) |
| June 2018 | - | -$26.38 M(-4.8%) | -$79.46 M(-0.7%) |
| Mar 2018 | - | -$27.72 M(+30.2%) | -$80.02 M(-0.2%) |
| Dec 2017 | -$80.20 M(-457.6%) | -$21.29 M(+422.7%) | -$80.20 M(-6.1%) |
| Sept 2017 | - | -$4.07 M(-84.9%) | -$85.40 M(-13.3%) |
| June 2017 | - | -$26.94 M(-3.4%) | -$98.55 M(-4.8%) |
| Mar 2017 | - | -$27.90 M(+5.3%) | -$103.48 M(-561.4%) |
| Dec 2016 | $22.43 M(-149.6%) | -$26.49 M(+53.8%) | $22.43 M(-37.9%) |
| Sept 2016 | - | -$17.23 M(-45.9%) | $36.12 M(-11.0%) |
| June 2016 | - | -$31.87 M(-132.5%) | $40.59 M(-33.9%) |
| Mar 2016 | - | $98.02 M(-865.4%) | $61.36 M(-235.7%) |
| Dec 2015 | -$45.21 M(+298.0%) | -$12.80 M(+0.4%) | -$45.21 M(+22.5%) |
| Sept 2015 | - | -$12.76 M(+15.0%) | -$36.89 M(+35.7%) |
| June 2015 | - | -$11.09 M(+29.7%) | -$27.19 M(+47.7%) |
| Mar 2015 | - | -$8.55 M(+90.6%) | -$18.41 M(+62.1%) |
| Dec 2014 | -$11.36 M(+106.7%) | -$4.49 M(+46.7%) | -$11.36 M(+65.3%) |
| Sept 2014 | - | -$3.06 M(+32.5%) | -$6.87 M(+80.3%) |
| June 2014 | - | -$2.31 M(+53.6%) | -$3.81 M(+153.6%) |
| Mar 2014 | - | -$1.50 M | -$1.50 M |
| Dec 2013 | -$5.50 M(+70.8%) | - | - |
| Dec 2012 | -$3.22 M | - | - |
FAQ
- What is Seres Therapeutics annual free cash flow?
- What is the all time high annual FCF for Seres Therapeutics?
- What is Seres Therapeutics annual FCF year-on-year change?
- What is Seres Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Seres Therapeutics?
- What is Seres Therapeutics quarterly FCF year-on-year change?
- What is Seres Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Seres Therapeutics?
- What is Seres Therapeutics TTM FCF year-on-year change?
What is Seres Therapeutics annual free cash flow?
The current annual FCF of MCRB is -$125.33 M
What is the all time high annual FCF for Seres Therapeutics?
Seres Therapeutics all-time high annual free cash flow is $22.43 M
What is Seres Therapeutics annual FCF year-on-year change?
Over the past year, MCRB annual free cash flow has changed by +$113.31 M (+47.48%)
What is Seres Therapeutics quarterly free cash flow?
The current quarterly FCF of MCRB is -$34.81 M
What is the all time high quarterly FCF for Seres Therapeutics?
Seres Therapeutics all-time high quarterly free cash flow is $123.65 M
What is Seres Therapeutics quarterly FCF year-on-year change?
Over the past year, MCRB quarterly free cash flow has changed by +$13.57 M (+28.04%)
What is Seres Therapeutics TTM free cash flow?
The current TTM FCF of MCRB is -$158.39 M
What is the all time high TTM FCF for Seres Therapeutics?
Seres Therapeutics all-time high TTM free cash flow is $61.36 M
What is Seres Therapeutics TTM FCF year-on-year change?
Over the past year, MCRB TTM free cash flow has changed by -$33.06 M (-26.38%)